Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants

Antiviral Research

Volumn 97, Issue 3, 2013, Pages 312-317

  Sonneveld, Milan J ^a   Rijckborst, Vincent ^a   Zwang, Louwerens ^a   Zeuzem, Stefan ^b   Jenny Heathcote, E ^c   Simon, Krzysztof ^d   Zoutendijk, Roeland ^a   Akarca, Ulus S ^e   Pas, Suzan D ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Core promoter; Immunomodulator; Peginterferon; Precore; Prediction of response

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B;

ADULT; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84873026024     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.023     Document Type: Article

References (29)

1. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., So T.M., Feinman S.V., Mach T., Akarca U.S., Schutten M., Tielemans W., van Vuuren A.J., Hansen B.E., Janssen H.L. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459-467.
2. Buster E.H., Flink H.J., Simsek H., Heathcote E.J., Sharmila S., Kitis G.E., Gerken G., Buti M., de Vries R.A., Verhey E., Hansen B.E., Janssen H.L. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am. J. Gastroenterol. 2009, 104:2449-2457.
3. Buster E.H., Hansen B.E., Lau G.K., Piratvisuth T., Zeuzem S., Steyerberg E.W., Janssen H.L. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
4. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., Iloeje U.H. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006, 295:65-73.
5. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., Iinuma K., Mushahwar I.K. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Meth. 2004, 115:217-222.
6. European Association For The Study Of The EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50:227-242.
7. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
8. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 2008, 48:335-352.
9. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-90.
10. Frelin L., Wahlstrom T., Tucker A.E., Jones J., Hughes J., Lee B.O., Billaud J.N., Peters C., Whitacre D., Peterson D., Milich D.R. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J. Virol. 2009, 83:1379-1392.
11. Fried M.W., Piratvisuth T., Lau G.K., Marcellin P., Chow W.C., Cooksley G., Luo K.X., Paik S.W., Liaw Y.F., Button P., Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428-434.
12. Hansen B.E., Buster E.H., Steyerberg E.W., Lesaffre E., Janssen H.L. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J. Med. Virol. 2010, 82:1135-1142.
13. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
14. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., Simon C., So T.M., Gerken G., de Man R.A., Niesters H.G., Zondervan P., Hansen B., Schalm S.W. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
15. Janssen H.L., Sonneveld M.J., Brunetto M.R. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?. Gut 2012, 61:641-645.
16. Kawabe N., Hashimoto S., Harata M., Nitta Y., Murao M., Nakano T., Shimazaki H., Arima Y., Komura N., Kobayashi K., Yoshioka K. The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection. J. Gastroenterol. 2009, 44:751-756.
17. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005, 352:2682-2695.
18. Liaw Y.F., Jia J.D., Chan H.L., Han K.H., Tanwandee T., Chuang W.L., Tan D.M., Chen X.Y., Gane E., Piratvisuth T., Chen L., Xie Q., Sung J.J., Wat C., Bernaards C., Cui Y., Marcellin P. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011, 54:1591-1599.
19. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996, 334:1422-1427.
20. Piratvisuth T., Marcellin P., Popescu M., Kapprell H.P., Rothe V., Lu Z.M. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol. Int. 2011, 55:1121-1131.
21. Sonneveld M.J., Janssen H.L. Chronic hepatitis B: peginterferon or nucleo(s)tide analogues?. Liver Int. 2010, 31(Suppl. 1):78-84.
22. Sonneveld M.J., Rijckborst V., Boucher C.A., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
23. Sonneveld M.J., Zoutendijk R., Janssen H.L. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J. Viral Hepat. 2011, 18:449-457.
24. Sonneveld M.J., Rijckborst V., Cakaloglu Y., Simon K., Heathcote E.J., Tabak F., Mach T., Boucher C.A., Hansen B., Zeuzem S., Janssen H.L. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir. Ther. 2012, 17:9-17.
25. Sonneveld, M.J., Rijckborst, V., Zeuzem, S., Heathcote, E.J., Simon, K., Senturk, H., Pas, S.D., Hansen, B.E., Janssen, H.L., 2012b. Presence of precore and core promoter mutants limits the probability of response to peginterferon in Hepatitis B e Antigen-positive chronic hepatitis B. Hepatology 56(1), 67-75. http://dx.doi.org/10.1002/hep.25636.
26. Sonneveld M.J., Wong V.W., Woltman A.M., Wong G.L., Cakaloglu Y., Zeuzem S., Buster E.H., Uitterlinden A.G., Hansen B.E., Chan H.L., Janssen H.L. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142:513-520.
27. Thompson A.J., Nguyen T., Iser D., Ayres A., Jackson K., Littlejohn M., Slavin J., Bowden S., Gane E.J., Abbott W., Lau G.K., Lewin S.R., Visvanathan K., Desmond P.V., Locarnini S.A. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51:1933-1944.
28. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Murad S.D., de Man R.A., Schalm S.W., Janssen H.L. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39:804-810.
29. Wong V.W., Wong G.L., Yan K.K., Chim A.M., Chan H.Y., Tse C.H., Choi P.C., Chan A.W., Sung J.J., Chan H.L. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:1945-1953.